Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as in comparison with imatinib, for the primary-line therapy of CML-CP. Five hundred and nineteen patients with newly diagnosed CML-CP were randomly assigned to receive dasatinib in a dose of a hundred mg at the time day by day https://chamfortw863pvb7.blogsvila.com/profile